LYEL
Lyell Immunopharma, Inc.Company with tickers: LYEL
CIK
1806952
CUSIP
55083R203
Shares Outstanding
23,334,087
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $2,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $44,263,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Research & Development | $36,604,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Operating Income | $-44,261,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Net Income | $-24,153,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| EPS (Basic) | $-1.10 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |
| EPS (Diluted) | $-1.10 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |